Novartis Foundation launches new leprosy strategy at symposium on disease elimination
29 November 2013 | By Novartis
Experts present lessons learned from past control programs and new approaches to eliminating diseases such as leprosy and malaria...
List view / Grid view
News
Daiichi Sankyo launches natural tetrahydrobiopterin agent Biopten® Granules 10%
29 November 2013 | By Daiichi Sankyo Company,
Biopten is a highly pure, chemically synthesized form of natural tetrahydrobiopterin (hereafter, BH4) that occurs naturally in the human body...
New malaria target identified with potential to prevent, block, and treat multiple stages of the malaria life cycle
28 November 2013 | By Novartis
Novartis scientists have discovered a new drug target for treating malaria...
GSK receives positive CHMP opinion for Cervarix™ two-dose schedule
28 November 2013 | By GlaxoSmithKline
GSK announced that the European Medicines Agency's Committee for Medicinal Products for Human Use is recommending marketing authorisation for a two-dose schedule in 9-14 year old girls for its cervical cancer vaccine, Cervarix™...
Mettler-Toledo to present live webinar entitled “Ensuring USP Compliance with Revised Chapters on Weighing”
27 November 2013 | By Mettler Toledo
Mettler-Toledo announced an upcoming webinar entitled “Ensuring USP Compliance with Revised Chapters on Weighing" with special guest presenter Mr. Gregory Martin, President of Complectors Consulting LLC...
Building a case of precision pipetting with Tecan’s Air LiHa
26 November 2013 | By kdm communications limited
Complementing the laboratory’s existing liquid displacement Freedom EVO platforms for DNA extraction, this new instrument will help to streamline the workflow and improve pipetting precision...
Hepatitis C: Boehringer Ingelheim’s faldaprevir granted accelerated assessment from European Medicines Agency
26 November 2013 | By Boehringer Ingelheim
The application for European marketing authorisation of faldaprevir* has been fully validated and granted accelerated assessment by the European Medicines Agency...
Cubist announces positive top-line results from phase 3 trial of investigational antibiotic ceftolozane/tazobactam…
25 November 2013 | By Cubist
“We are very pleased with these positive results, which represent a significant milestone for both ceftolozane/tazobactam and Cubist...”
Sanofi and Regeneron’s Dupilumab named “Clinical Advance of the Year” by Scrip Intelligence
25 November 2013 | By Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Phase 2a study of dupilumab in asthma was named "Clinical Advance of the Year" by Scrip Intelligence at the 9th annual Scrip Awards. The award was announced last week by Scrip, a leading pharmaceutical…
Teva comments on recent article
25 November 2013 | By TEVA
Teva Pharmaceutical Industries Ltd. issued the following statement regarding an article published by The Marker...
GSK Responds to FDA decision on Avandia (rosiglitazone)
25 November 2013 | By GlaxoSmithKline
The U.S. Food and Drug Administration has eased restrictions on patient access to Avandia (rosiglitazone)...
H5N1 vaccine approved by the U.S. FDA as pandemic influenza preparedness measure
25 November 2013 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the FDA has approved its pandemic Influenza A Virus Monovalent Vaccine...
Novo Nordisk and Roche Diabetes Care are joining forces to make insulin pump therapy simpler for people with diabetes
22 November 2013 | By Novo Nordisk
Insulin aspart PumpCart® is a 1.6 ml prefilled insulin pump cartridge containing the rapid-acting insulin aspart...
OLYSIO™ (simeprevir) receives FDA approval for combination treatment of chronic hepatitis C
22 November 2013 | By Johnson & Johnson
OLYSIO™ works by blocking the viral protease enzyme that enables the hepatitis C virus (HCV) to replicate in host cells...
CHMP determines Dimethyl Fumarate in TECFIDERA® to be a new active substance in the European Union
22 November 2013 | By Biogen Idec
This designation will provide 10 years of regulatory exclusivity for TECFIDERA in the European Union...
